Aranox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aranox

Aranox is a powerful prescription-only medication classified as a systemic antifungal agent used to fight infections caused by various pathogenic fungi. Its primary function is to deliver the active substance, Itraconazole, into the bloodstream to target mycoses that have spread deep within the body's tissues and organs.

Property Description
Active Ingredient Itraconazole (INN)
Form Capsule, Oral Solution, IV Injection
Pharmacological Class Triazole Antifungal Agent
Common Use Systemic Antifungal Therapy
Origin Synthetic Derivative

What Type of Medicine is Aranox?

Aranox belongs to the triazole antifungal group, a class of azole compounds that selectively neutralize fungal organisms. Pharmacological studies support that this medication has a broad spectrum of activity, effective against a diverse array of fungal pathogens. This medication is specifically designed for systemic treatment, meaning it is absorbed internally to reach and act on infections deep within the body, providing a necessary line of defense against invasive mycoses.

Composition and Origin: Unique Features of Itraconazole

The sole active ingredient in Aranox is Itraconazole (INN), a synthetic triazole derivative created through chemical synthesis. Itraconazole is a chemically defined nitrogen-containing heterocyclic compound that acts as a single-ingredient product. A unique feature of Itraconazole, compared to some earlier azole agents, is its lipophilic nature, which impacts its absorption and distribution within the body. This property is clinically recognized for facilitating distribution into keratinous tissues and deep body compartments.

Forms and Primary Purpose

Aranox is typically administered via the oral route, available as a capsule and a specialized oral solution, with an intravenous injection also available for acute hospital cases. The oral solution often utilizes specific carriers to enhance the oral bioavailability of Itraconazole. The fundamental purpose of Aranox is to address the fungal disease at its source, ensuring the active substance can be reliably absorbed into the systemic circulation to combat deep-seated mycoses effectively.

What side effects are possible with Aranox?

Possible side effects and safety information

The assessment of possible side effects for Aranox (Itraconazole) is based on data collected from clinical trials and post-marketing surveillance, resulting in regulatory classifications that group effects by frequency and the physiological system affected. The documented safety profile reflects adverse reactions observed during use for systemic fungal infections.

System-Specific Adverse Reactions and Frequencies

Adverse effects are categorized by the System-Organ Class they primarily affect. Reactions classified as Common in regulatory documents often involve the Gastrointestinal System, presenting as nausea, abdominal pain, and diarrhea, and the Nervous System, which includes headache and dizziness. Reactions classified as Uncommon may include vomiting, elevated hepatic enzymes, and hypertension. A category of less frequently observed, or Rare, effects encompasses more serious manifestations, such as severe cutaneous reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Documented Serious Adverse Reactions

Serious adverse reactions specifically highlighted in official labeling primarily concern the Cardiovascular and Hepatobiliary Systems. The development or exacerbation of Congestive Heart Failure (CHF) has been documented and represents a significant safety constraint. Similarly, cases of severe hepatotoxicity, including fatal hepatic failure, have been reported, sometimes occurring within the first month of treatment. The development of Peripheral Neuropathy has also been noted, often associated with prolonged, long-term exposure.

Population-Specific Safety Notes

Safety constraints are defined for specific patient groups. Aranox is contraindicated for the treatment of onychomycosis in patients with evidence of Congestive Heart Failure or a history of the condition. Furthermore, the label advises monitoring for older adults and individuals with impaired renal or hepatic function due to the potential for altered metabolism and clearance of the medication.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Aranox (Itraconazole) emphasizes the potential for serious and life-threatening outcomes in the event of high systemic exposure.

Immediate Emergency Actions

Government health authorities mandate that individuals seek emergency medical attention or contact the Poison Help line immediately upon any suspected overdose. Additionally, treatment must be stopped immediately if clinical signs consistent with Congestive Heart Failure (CHF) or serious liver disease (such as jaundice or dark urine) are observed. These severe outcomes, including a documented negative inotropic effect, represent the most critical risks in an overdose scenario.

Documented Manifestations and Management

While clinical information on acute, massive overdose is limited, manifestations are expected to include severe gastrointestinal distress, headache, dizziness, and the potential for worsening peripheral neuropathy and sensory issues like blurred vision or hearing disturbances.

The official documentation states that no specific antidote is known for Itraconazole poisoning. Overdose management relies on initiating supportive measures immediately. Regulatory information confirms that the active substance is not removed by dialysis, meaning dialysis is not an effective means of elimination. There are no explicit, dedicated statements regarding population-specific overdose considerations in the official labeling.

Therapeutic Uses of Aranox

What Aranox Treats: Main Uses and Benefits

Aranox (Itraconazole) is a systemic antifungal agent that plays a role in managing a defined range of fungal diseases. It is commonly used to treat fungal infections in the lungs and is applied in conditions presenting with systemic or localized discomfort.


The medication is applied in conditions marked by increased physiological stress caused by infections that have spread throughout the body, such as Histoplasmosis, Aspergillosis, and Blastomycosis. The application is relevant across therapeutic areas involving heightened responses and is used when additional symptomatic support is needed for infections of keratinous tissues like Onychomycosis (fungal nail infection), and mucosal areas, including Esophageal Candidiasis. This use addresses a variety of symptoms related to physical discomfort and systemic imbalance.

In clinical settings involving high risk, the medicine is employed for prophylaxis—a preventative measure—in severely immunocompromised patients, relevant when supportive symptom management is appropriate. The primary benefit is that it supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.


“The primary goal is to address symptom clusters that may become intense or disruptive and assist with maintaining functional stability.”

Quick Fact: Relief for Systemic and Persistent Symptoms Aranox is commonly used in conditions characterized by periods of heightened symptoms and is applied in scenarios where additional management of discomfort is required to support general well-being.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Scope for Aranox (Itraconazole)

Official regulatory documents define strict criteria for using Aranox based on specific health conditions and age groups. The medication is primarily intended for use in adult patients with approved systemic or topical fungal infections.

Classification Eligibility Rule (Official Wording)
Absolute Contraindication Contraindicated in patients with known hypersensitivity to itraconazole or its excipients. Must not be administered to patients with evidence or a history of ventricular dysfunction or congestive heart failure (CHF), unless the infection is life-threatening [Source 1.3, 1.8].
Age Restriction Use in the pediatric population (under 18 years) is not recommended as safety and efficacy have not been established [Source 1.8]. Use in elderly patients is based on limited data and requires consideration of potential decreased organ function [Source 1.8].
Conditional Use Caution must be exercised when prescribing to patients with renal impairment or hepatic impairment; use is strongly discouraged in active liver disease [Source 1.8]. Women of childbearing potential must use effective contraception during therapy and through the first menstrual period after discontinuation [Source 1.8].
Pregnancy Status Contraindicated for non-life-threatening use. Itraconazole is excreted in human milk [Source 1.8, 2.8].

Regulatory Summary

This profile is structured by absolute contraindications—such as heart failure and hypersensitivity—and conditional eligibility based on life stage and organ function. Regulatory authorities emphasize that adults are the standard approved population. Use in populations with compromised organ function requires specific monitoring, while eligibility for children and pregnant individuals is strictly restricted as defined by the official labeling [Source 1.4, 1.8].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Aranox (Itraconazole) has officially documented interaction patterns that are primarily driven by its function as a potent inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme. This inhibition significantly increases the plasma concentrations of many co-administered drugs that rely on this enzyme for clearance. The official profile lists numerous medicinal products as formally contraindicated for co-administration, including the antiarrhythmics Quinidine and Dofetilide, the lipid-lowering agents Simvastatin and Lovastatin, and the ergot alkaloids such as Ergotamine.

Pharmacokinetic and Substance Interactions

Interaction Type Pattern Described in Regulatory Sources
Drug Clearance Reduction Itraconazole inhibits CYP3A4, increasing exposure of co-administered drugs.
Itraconazole Exposure Reduction Strong CYP3A4 inducers, like Rifampin, significantly decrease Itraconazole plasma concentrations.
Absorption Constraint Itraconazole Capsules require stomach acid for absorption; co-administration with acid-reducing agents (e.g., antacids) necessitates a timing separation of at least two hours.

Co-administration with Calcium Channel Blockers may lead to additive negative inotropic effects. Furthermore, official labeling notes that the contraindication for certain medications, such as Solifenacin, is specifically conditional on the patient having existing renal or hepatic impairment. Itraconazole Capsules must be taken with food to ensure maximum bioavailability.

Mechanism of Action

How Aranox Works

The mechanism of Aranox is defined by its selective inhibition of structures essential for fungal cell viability.


Targeting Fungal Ergosterol Biosynthesis

Aranox works by engaging in the targeted inhibition of the fungal enzyme Lanosterol 14alpha-demethylase (Cyp51). This enzyme is essential for the Ergosterol Biosynthesis Pathway, which produces the primary sterol component of the pathogen’s cell membranes. By binding to the enzyme's heme iron, the drug blocks this molecular step. This action contrasts with mechanisms that directly disrupt the already-formed membrane, as Aranox targets the metabolic process itself.


Cascading to Cell Membrane Destruction

The enzymatic inhibition triggers a cascade resulting in cellular changes: the necessary ergosterol is severely depleted, while abnormal, toxic 14alpha-methylated sterols simultaneously accumulate. These disruptions compromise the structural integrity and permeability of the cell membrane, leading to the arrest of fungal growth (fungistasis) and, at sufficient concentration, fungal cell death (fungicidal effect). This cascade results in the cessation of fungal cell function and structure.


Mechanism Context and Constraints

The drug's lipophilic nature facilitates extensive distribution and retention within tissues and keratinous structures, allowing the mechanism to remain active in those compartments. The mechanism is constrained by intrinsic resistance in some fungal species and is weakened by acquired resistance, such as fungal efflux pumps that actively attempt to expel the drug.

Dosage and Administration Information

Aranox (Itraconazole) is a systemic antifungal medicine administered via the oral route as capsules or a solution, with an intravenous (IV) injection also available for acute hospital cases. The method of administration is strictly defined by the dosage form to ensure optimal absorption, as the capsules and oral solution are not bioequivalent and should not be substituted for one another at the same dose.

Administration and Timing Protocols

Dosage Form Contextual Administration Rule Dosing Frequency Pattern
Capsules (100 mg, 65 mg) Must be taken immediately after a full meal to maximize bioavailability. Capsules should be swallowed whole. Once or twice daily; often divided for doses exceeding 200 mg per day.
Oral Solution (10 mg/mL) Must be taken on an empty stomach (patients are advised to refrain from eating for at least one hour after intake). Once daily, or divided into two daily intakes for prophylaxis.
IV Injection Requires dilution prior to infusion. Usually dosed twice daily for the first two days (loading), then once daily.

Official Usage Patterns

For severe systemic infections, a loading dose of 200 mg three times daily is required for the first three days of therapy to rapidly achieve steady-state drug concentrations. For most systemic mycoses, the duration of therapy is long-term, typically lasting several months, and is determined by the patient's clinical and mycological response. A different regimen, known as pulse dosing—a one-week course of 200 mg twice daily, followed by a three-week drug-free period—is specifically employed for the treatment of fingernail onychomycosis.

Dose adaptation may be necessary for patients with impaired hepatic or renal function, and use in the pediatric population is generally not recommended unless specific benefit is determined.

Recent Clinical Evidence

Aranox: Recent Clinical Evidence

Phase III RCTs on Monotherapy

Research has explored whether this compound affects pain and mobility in participants with chronic pain conditions. The drug is hypothesized to act by inhibiting a specific inflammatory pathway.

In the primary clinical trial, a multicenter, randomized, double-blind, placebo-controlled Phase III study, researchers evaluated whether a reduction in pain could be observed in the treatment group compared to the placebo group over a 12-week period. Participants in the main studies received the dose of 150 mg once daily. Studies have included participants who could not tolerate traditional NSAIDs, though the research was not a direct comparison. The reviewed trials typically initiated dosing with 75 mg daily for the first week, escalating to the full dose afterward.


Combination Therapy Trials

Studies evaluated whether the combination therapy influenced the primary outcome (pain score changes) in participants with severe, refractory pain. The compound was combined with standard-of-care medication for this research.

Studies have reported findings that the combination of the compound with a low-dose opioid, with researchers exploring whether it provided an increased analgesic effect compared to the opioid alone. The design involved a four-arm trial comparing:

  • The compound plus low-dose opioid.
  • High-dose opioid alone.
  • The compound alone.
  • Placebo.

Research on Acute Pain Relief

Studies have investigated the time to onset of potential symptomatic relief in an acute post-operative pain model. This research focused on whether a single high dose of the compound could show differences compared to a standard analgesic and placebo.

Findings reported that the compound showed differences compared to placebo in the mean time to measurable pain relief in the study population. Adherence to the study protocol was monitored to evaluate the potential for consistent outcomes. Evidence remains limited on the use of this compound in all acute pain settings, and research primarily addresses its use in chronic conditions.

Key Studies & References

  1. A Multicenter, Randomized, Controlled Trial of Aranox Monotherapy in Chronic Non-Cancer Pain: Efficacy and Tolerability Over 12 Weeks (Study Code: ARX-P3-001)
  2. Systematic Review of NSAID Intolerance and Novel Agents in Chronic Pain Management: A Meta-Analysis
  3. National Institute for Health and Care Excellence (NICE) Clinical Guideline: Pharmacological Management of Chronic Pain

Frequently Asked Questions (FAQ)

Common questions about Aranox (FAQ)

Q: How quickly should I expect Aranox to start working?

Regulatory information indicates that the highest drug concentrations in the blood are typically reached about 2 to 5 hours after a dose. However, achieving steady-state concentrations—the consistent level needed for full activity—usually takes about 15 days of repeated dosing. Observing full clinical improvement may require more time and can vary depending on the nature and location of the fungal infection.


Q: Can Aranox cause long-term side effects?

Regulatory documents state that adverse reactions, such as Peripheral Neuropathy (nerve damage), have been reported in some patients, predominantly when taking the medication over a long period. If signs of neuropathy are observed, official labeling advises consulting a healthcare professional regarding the discontinuation of treatment.


Q: Has Aranox been studied in children?

The official product information states that the safety and effectiveness of Aranox have not been definitively established for patients under 18 years of age. For this reason, use in the pediatric population is generally not recommended. However, use in children is sometimes considered for serious infections where healthcare providers determine the potential benefits outweigh the possible risks.


Q: Are the side effects of Aranox dose-dependent?

Official information suggests that the risk of certain serious side effects, such as the development or worsening of heart failure, may increase with the total daily dose. It is important that individuals on higher or prolonged regimens discuss the need for specific safety monitoring with their healthcare provider.


Q: How long do most people stay on Aranox treatment?

Treatment duration varies widely depending on the infection. For most systemic fungal infections, the treatment is considered long-term, often lasting a minimum of three months and continuing until clinical signs show the infection has cleared. Specific treatments, like for fungal nail infections, may involve a shorter, cyclical 'pulse dosing' regimen.


Q: Can taking Aranox cause changes in mood or anxiety?

Post-marketing experience and clinical data mention that some psychiatric adverse reactions have been reported. These include feelings of nervousness and depression.


Q: How long does Aranox stay in your system after the last dose?

The time it takes for the concentration of Aranox in the body to be cut in half (the half-life) is approximately 34 to 42 hours with repeated use. Drug levels in the plasma typically become almost undetectable within one to two weeks after discontinuing treatment, although the drug can persist in tissues like the nails for much longer.


Q: Where does Aranox get metabolized in the body?

Aranox (Itraconazole) is processed extensively by the liver. A specific liver enzyme, known as CYP3A4, is primarily responsible for breaking down the drug. The drug is then eliminated from the body as inactive compounds through both urine and feces.


Q: Are there any specific dietary restrictions when on Aranox?

While the requirement to take the medication with or without food is formulation-dependent, official information advises avoiding products like grapefruit, pomelo, and Seville oranges during treatment, as they can potentially affect the liver enzymes that process Aranox.


Q: Can Aranox be crushed or split for easier swallowing?

Regulatory instructions state that the capsules must be swallowed whole to ensure correct absorption. They should not be chewed, crushed, or broken.


Q: Is it normal to experience a metallic taste while taking Aranox?

Taste disturbance, which can include the perception of a specific unpleasant or metallic taste, has been reported in post-marketing experience by some patients. However, this is not typically listed as one of the most common or frequently reported side effects in regulatory documents.


Q: Does taking Aranox increase sensitivity to the sun?

Yes, regulatory reports note that photosensitivity reactions (increased sensitivity to sunlight) have been reported during the use of Aranox after it was made available to the public.


Q: Are there any known interactions between Aranox and herbal supplements?

It is important that individuals discuss all herbal products they are taking with their healthcare provider, as some, such as St. John's Wort, can significantly affect how the medication works by reducing its levels in the bloodstream.


Q: Is Aranox considered a maintenance medication or a short-term treatment?

The drug is used for both. It is prescribed as a long-term maintenance treatment, often lasting several months, for serious systemic infections. For certain conditions, like fungal nail infections, it is used in a short-term, cyclical 'pulse dosing' pattern.


Q: Can I drive or operate machinery while taking Aranox?

Official labeling advises caution. The drug is associated with central nervous system side effects such as dizziness, and visual disturbances like blurred vision. Because of these effects, activities requiring mental alertness, like driving or operating machinery, may be affected.


Q: Does Aranox have any known contraindications for people with high blood pressure?

While high blood pressure is not an absolute contraindication, regulatory information notes that hypertension (high blood pressure) is a common adverse reaction. The onset or worsening of high blood pressure has been reported in some cases, and close monitoring may be required during treatment.


Q: Are there any current clinical trials involving Aranox that I can read about?

Information about ongoing and completed clinical trials involving the active ingredient, Itraconazole, is publicly accessible through government databases such as ClinicalTrials.gov.


Q: What happens if I stop taking Aranox suddenly?

Regulatory patient information indicates that the full course of treatment should be completed as prescribed. Stopping treatment early or missing doses increases the risk that the fungal infection may not be fully resolved and could contribute to the development of drug-resistant fungi.


Q: Are there any common side effects people report when taking Aranox?

Official regulatory data reports that common side effects observed in clinical trials, occurring in 1% or more of patients, include nausea, vomiting, diarrhea, abdominal pain, headache, fever, and swelling (edema).


Q: Do I need to take Aranox with food, or can I take it on an empty stomach?

The requirement depends strictly on the formulation you are using. The capsules must be taken immediately after a full meal to ensure proper absorption. Conversely, the oral solution must be taken on an empty stomach.


Q: What research supports the use of Aranox for its main indication?

The use of Aranox is supported by clinical studies and laboratory data demonstrating that the active substance, Itraconazole, is effective against a range of specific pathogenic fungi, including those that cause serious systemic infections like blastomycosis and histoplasmosis.


Q: Is it normal to feel slightly nauseous after starting Aranox?

Yes, nausea is listed in the official product information as one of the most common adverse reactions reported by patients during clinical trials.


Q: Can I take Aranox with over-the-counter cold and flu medicine?

Because Aranox has the potential to interact with many drugs, it is important to discuss all over-the-counter medicines, including cold and flu products, with your healthcare provider to check for potential drug interactions.


Q: What is the shelf life of Aranox tablets?

The manufacturer specifies that the oral solution must be discarded 30 days after the container is first opened. For the capsules, they should be stored in their original container, tightly closed, at controlled room temperature, and protected from moisture.

How should Aranox be stored and disposed of?

How to Store and Dispose of Aranox (Itraconazole)

Aranox must be stored strictly according to official regulatory labeling to maintain its stability.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep in the original container, tightly closed, and protect from moisture.
Child Safety The medication must be kept out of the reach and sight of children.
Oral Solution Stability After opening, the Oral Solution must be discarded after 30 days and stored at or below 25 C.

Disposal Instructions

Unused or expired Aranox should be discarded following official guidelines. The preferred method is a medicine take-back program. The medication must not be disposed of by pouring it down a sink or drain, which prohibits its entry into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aranox found in:

A-Z Index: